Capstone Therapeutics Corp.
| OTC Markets: CAPS
Capstone Therapeutics Corp. is a biotechnology company that develops a pipeline of novel therapeutic peptides aimed at helping patients with under-served medical conditions. Currently, the company has entered into a joint venture, LipimetiX Development LLC to develop Apo E mimetic peptide molecule AEM-28 and its analogs. Apolipoprotein E is a 299 amino acid protein that plays an important role in lipoprotein metabolism. AEM-28 is a 28 amino acid mimetic of Apo E that contains a domain that anchors into a lipoprotein surface while also providing the Apo E binding domain that is removed by heparin sulfate receptors in the liver. AEM-28 as an Apo E mimetic has the potential to restore the ability of these atherogenic lipoproteins to be cleared from the plasma, completing the reverse cholesterol transport pathway, and thereby reducing cardiovascular risk. The company was founded in July 1987 and is headquartered in Tempe, AZ.